For instance, platin-based treatment irrespective of BRCA1/2 status has been standard for groups of the ovarian and pancreatic cancer patients, while traditionally not for the breast cancer patients (Gennari et al., 2021; Colombo et al., 2019). The gene discussed is BRCA1; the disease is pancreatic neoplasm.